Monday
June 7
1:00 - 1:55pm ET

ASCO highlights: The biggest breakthroughs; the worst setbacks

Every year the biopharma industry turns to ASCO to help define where cancer drug R&D is headed. Endpoints News will bring together a group of experts to discuss the most important presentations at the conference, with insights on the winners and losers at ASCO 21.

Panelists

Howard (Jack) West
Howard (Jack) West
Clinical Executive Director, AccessHope
City of Hope Comprehensive Cancer Center
John Connolly
John Connolly
Chief Scientific Officer
Parker Institute for Cancer Immunotherapy
Dietmar P. Berger
Dietmar P. Berger
Chief Medical Officer, Global Head of Development
Sanofi
Leena Ghandi
Leena Gandhi
Director, Center for Cancer Therapeutic Innovation
Dana-Farber Cancer Institute
George Demetri
George Demetri
Director, Center for Sarcoma and Bone Oncology
Dana-Farber Cancer Institute
John Carroll
John Carroll
Editor & Founder
Endpoints News
Monday
June 7
2:00 - 3:00pm ET

BCMA: What’s happening in the hottest field in oncology?

After CD19, BCMA became the cancer target that everyone wanted to hit. And even with a couple of approvals here, there’s a slew of rivals looking to come out on top. Endpoints Editor John Carroll will examine 4 of the leading programs in a look at the latest cutting edge drugs being tested in the clinic.

Panelists

Natalie Sacks
Natalie Sacks
Chief Medical Officer
Harpoon
Peter F. Lebowitz
Peter F. Lebowitz
Global Therapeutic Area Head, Oncology
Janssen Research & Development
Kristen M. Hege
Kristen M. Hege
Senior Vice President, Early Clinical Development, Hematology/Oncology and Cell Therapy
Bristol Myers Squibb
Rafael G. Amado
Rafael G. Amado
Executive Vice President of R&D and CMO
Allogene
Andres Sirulnik
Andres Sirulnik
Senior Vice President, Translational and Clinical Sciences, Hematology
Regeneron
John Carroll
John Carroll
Editor & Founder
Endpoints News
Thomas VanCott
presenting sponsor
Thomas VanCott
Global Head of Product Development, Cell & Gene Therapy
Catalent Cell & Gene Therapy
Tuesday
June 8
11:00am - 12:00pm ET

The resurgence of theranostics: Challenges and successes of clinical application

Theranostics, the use of radiolabeled targeted compounds, combines diagnostic imaging with targeted therapy. The acquisition of Endocyte and AAA by Novartis and the recent positive phase 3 results with 177Lu-PSMA-617 have helped a once unfamiliar field become more attractive and accessible.

In this roundtable discussion, the panelists will review the unique challenges and requirements involved with the non-clinical and clinical development of Theranostics, including:

  • Discussing the different targeting platforms and strategies used to develop new Theranostic agents.
  • Reviewing the potential of combination therapies that utilize the mechanism of action alpha- and beta-emitting radiation.
  • Addressing normal organ radiation dose limits, the use of dosimetry and biomarkers to monitor kidney/marrow damage and whether current radiation limits require updating.

Panelists

Germo Gericke
Germo Gericke
CMO of Advanced Accelerator Applications
Novartis
John Valliant
John Valliant
Founder and CEO
Fusion Pharmaceuticals
Deborah Charych
Deborah Charych
Founder and CTO
RayzeBio
Arsalan Arif
moderator
Arsalan Arif
Publisher & Founder
Endpoints News
Ohad Ilovich
Ohad Ilovich
Sr. Director of Translational Research
Invicro
SHARE ON